Ultragenyx is trading 4.1% down at $24.77 today as the stock undergoes a typical post-earnings reversal following yesterday's significant rally.
- The company reported record Q2 revenue of $214 million, which beat analyst expectations and led to a reaffirmation of its 2026 financial guidance.
- Today's decline is characterized by profit-taking after a strong earnings-driven pop, with no new negative catalysts reported.
- The move comes amid a mixed performance for broader biotech peers and major market indices.